Skip to content
ClosedNo longer accepting applications

Assessment of Host-targeted Nanobody Therapeutics

DEPT OF DEFENSE

About this archived opportunity

Numerous neurotropic viral families are considered high priority pathogens to the Department of War (DOW), but the therapeutic decelopment in stymied by the difficulty of trafficking into into the Central Nervous System (CNS). This is mediated primarily by blood-brain barrier (BBB) tight junctions that prevent large molecules entry into the parenchymal space. However, the CNS has significant physiologically needs in the form of energy, oxygen and other molecular components. See Statement of Objectives (SOO) for specific information.

Historical details

Status
Closed
Deadline
January 21, 2026
First captured
January 11, 2026
Publisher reference
37a309976cd744b89e169bddc7ba06fb

Eligibility: No Set aside used. NONE

This opportunity has closed

Assessment of Host-targeted Nanobody Therapeutics

by DEPT OF DEFENSE

Get notified when similar opportunities open

We'll save this search and email you when new assessment, host, targeted opportunities are posted. Free.

Refine this search